Skip links

Partner with us.

Refer a patient.

Intravenous ketamine is a safe therapy that’s proven effective when other methods aren’t. A growing body of scientific research shows ketamine infusions work best for patients who are suffering from depression, anxiety, burnout, postpartum mental health conditions, PTSD, OCD, migraines, or chronic pain and are ready for change.

Teaming up with you, the primary provider, we strive to integrate these transformative treatments into a comprehensive, individualized mental health care plan. Operating under the principles of patience, presence, and empathy, we prioritize post-treatment followup and use the Osmind EHR software and mood-tracking app to integrate online support and ongoing patient-provider communication into our care.

If you’re a provider with a patient who could benefit from ketamine treatments, please call us at 650-419-3330 to learn more.

Partner with us!

There is a growing community of California therapists who meet virtually each month to support each other and discuss ketamine-assisted psychotherapy techniques, research, cases, and more.

Soft Reboot Wellness Mental Health Partnership PDF

Verification of Diagnosis & Confirmation of Care

Ketamine Research and Resources

  1. Kadriu B, Greenwald M, Henter ID, Gilbert JR, Kraus C, Park LT, Zarate CA. Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants. Int J Neuropsychopharmacol. 2021 Jan 20;24(1):8-21. doi: 10.1093/ijnp/pyaa087. PMID: 33252694; PMCID: PMC7816692.
  2. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000 Feb 15;47(4):351-4. doi: 10.1016/s0006-3223(99)00230-9. PMID: 10686270.
  3. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006 Aug;63(8):856-64. doi: 10.1001/archpsyc.63.8.856. PMID: 16894061.
  4. Phillips JL, Norris S, Talbot J, Birmingham M, Hatchard T, Ortiz A, Owoeye O, Batten LA, Blier P. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. Am J Psychiatry. 2019 May 1;176(5):401-409. doi: 10.1176/appi.ajp.2018.18070834. Epub 2019 Mar 29. PMID: 30922101.
  5. Sakurai H, Jain F, Foster S, Pedrelli P, Mischoulon D, Fava M, Cusin C. Long-term outcome in outpatients with depression treated with acute and maintenance intravenous ketamine: A retrospective chart review. J Affect Disord. 2020 Nov 1;276:660-666. doi: 10.1016/j.jad.2020.07.089. Epub 2020 Jul 20. PMID: 32871698.
  6. Matveychuk D, Thomas RK, Swainson J, Khullar A, MacKay MA, Baker GB, Dursun SM. Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Ther Adv Psychopharmacol. 2020 May 11;10:2045125320916657. doi: 10.1177/2045125320916657. PMID: 32440333; PMCID: PMC7225830.
  7. Jones JL, Mateus CF, Malcolm RJ, Brady KT, Back SE. Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review. Front Psychiatry. 2018 Jul 24;9:277. doi: 10.3389/fpsyt.2018.00277. PMID: 30140240; PMCID: PMC6094990.
  8. Abdollahpour A, Saffarieh E, Zoroufchi BH. A review on the recent application of ketamine in management of anesthesia, pain, and health care. J Family Med Prim Care. 2020;9(3):1317-1324.
  9. Gerhard DM, Pothula S, Liu R-J, et al. GABA interneurons are the cellular trigger for ketamine’s rapid antidepressant actions. Journal of Clinical Investigation. 2020;130(3):1336-1349.
  10. Dore J, Turnipseed B, Dwyer S, et al. Ketamine assisted psychotherapy (Kap): patient demographics, clinical data and outcomes in three large practices administering ketamine with psychotherapy. Journal of Psychoactive Drugs. 2019;51(2):189-198.
  11. Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. J Affect Disord. 2021 Jan 1;278:542-555. doi: 10.1016/j.jad.2020.09.071. Epub 2020 Sep 23. Erratum in: J Affect Disord. 2020 Nov 20;: PMID: 33022440; PMCID: PMC7704936.
  12. Revealing the Mind: The Promise of Psychedelics

What to expect on your Journey

When you feel called to the path toward transformation, we’re here, waiting to escort you on the journey.

Call Us